VENUSREM - Venus Remedies

📊 NSE: VENUSREM 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/14/2025 15:03

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 7.72% YoY to ₹647.89 Cr in FY25, while standalone revenue grew 11.17% to ₹639.46 Cr. Growth was driven by critical care, anti-infectives, and oncology divisions.

Geographic Revenue Split

Not disclosed in specific percentages, but the company reported strong export momentum and expanded marketing efforts in key global markets including Europe, ASEAN, and Africa.

Profitability Margins

Net Profit Margin improved from 5.20% in FY24 to 7.96% in FY25. Consolidated Profit After Tax (PAT) grew 59.05% YoY to ₹45.31 Cr, while standalone PAT grew 72.34% to ₹52.56 Cr.

EBITDA Margin

EBITDA increased 18.7% YoY from ₹71.18 Cr in FY24 to ₹84.49 Cr in FY25, representing an EBITDA margin of approximately 13.04%.

Capital Expenditure

Not disclosed in absolute INR Cr for future periods, but the company is prioritizing 'sustainability-first construction' for all future sites and investing in digital infrastructure.

Credit Rating & Borrowing

The company was rated 'CRISIL D (ISSUER NOT COOPERATING)' as of October 2020. Interest costs are maintained low, at less than 1% of total revenues.

⚙️ Operational Drivers

Raw Materials

Specific names not disclosed; categorized as 'imported raw materials' and components for pharmaceutical formulations.

Key Suppliers

Not disclosed in available documents; company uses multiple supplier contracts to mitigate disruption risks.

Capacity Expansion

Current capacity not disclosed in units; expansion plans focus on the Global Venus Fulfilment Centre (Global VFC) and automation of critical processes.

Raw Material Costs

Cost of material consumed remained largely at the previous year's level despite a 7.72% increase in consolidated revenue, indicating improved procurement efficiency.

Manufacturing Efficiency

Internal rejection rates were eliminated (0 rejections) in FY25, down from 1 in FY24 and 2 in FY23, through strengthened in-process controls.

📈 Strategic Growth

Expected Growth Rate

7.72%

Growth Strategy

Growth will be achieved through the commercialization of intellectual property assets, completion of AMR licensing milestones (final €1.1 Cr payment), and expansion of digital literature with QR codes in domestic markets.

Products & Services

Pharmaceutical formulations in critical care, anti-infectives, oncology, and research-based products like VRP-034.

Brand Portfolio

Venus Remedies, Venus Pharma GmbH, Venus Care.

New Products/Services

VRP-034 received USFDA QIDP designation; company is focusing on marketing authorisations for IP-led formulations.

Market Expansion

Targeting further growth in European markets and domestic expansion through digital branding and social media strategies.

Strategic Alliances

AMR Licensing agreement (milestone completed with €1.1 Cr payment); collaboration with government Skill Sector councils for digital assessments.

🌍 External Factors

Industry Trends

The industry is shifting toward digital literature, automated quality management, and stricter compliance with EU GMP Annexe I and Schedule M updates.